Home / Business and Economy / US Biotech Eyes Hong Kong IPO Leap
US Biotech Eyes Hong Kong IPO Leap
22 Jul
Summary
- US biotech Axiom Biosciences plans Hong Kong IPO in 2027.
- Company seeks biotech-focused investors in Asia.
- Hong Kong's IPO market shows strong growth in biotech.
Axiom Biosciences, a San Diego-based firm specializing in regenerative and genetic medicines, is charting a unique course by planning to go public in Hong Kong by 2027. This will be followed by a secondary listing in the United States by 2029. The company's leadership views this as a "contrarian" strategy to access specialized biotech investors and deepen engagement with Asian partners.
Company founder and CEO Remo Moomiaie-Qajar highlighted that while U.S. science leads, its funding mechanisms lag. He pointed to Hong Kong's robust regulatory standards and recent successful biopharma listings as indicators of a mature ecosystem. This move comes as public markets offer a crucial alternative for capital raising, particularly when venture funding becomes more constrained for companies progressing through costly clinical trials.
While the U.S. remains the preeminent global hub for biotech capital, Hong Kong's appeal is growing. Reforms have streamlined its IPO process, and the Hang Seng Biotech Index has seen significant gains, outperforming U.S. benchmarks since January 2025. Firms are drawn to the expanding investor base and proximity to Chinese pharmaceutical collaborators, which could accelerate development and reduce costs.
